JP MORGAN/CALL/BECTON DICKINSON AND CO./285/0.1/17.01.25 Share Price

Warrant

DE000JL1MJ07

Market Closed - Bid/Ask 08:06:58 21/05/2024 BST After market 19:49:58
0.79 EUR +3.95% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./285/0.1/17.01.25 0.745 -5.70%
Current month-15.56%
1 month-19.15%
Date Price Change
21/05/24 0.79 +3.95%
20/05/24 0.76 -5.00%
17/05/24 0.8 -9.09%
16/05/24 0.88 +8.64%
15/05/24 0.81 -5.81%

Delayed Quote Börse Stuttgart

Last update May 21, 2024 at 08:06 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JL1MJ0
ISINDE000JL1MJ07
Date issued 05/04/2023
Strike 285 $
Maturity 17/01/2025 (241 Days)
Parity 10 : 1
Emission price 1.95
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 4.99
Lowest since issue 0.76
Spread 0.05
Spread %6.41%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
237.1 USD
Average target price
279 USD
Spread / Average Target
+17.66%
Consensus